FDA clears AngioDynamics' device to reduce blood clots

08/21/2013 | Post-Star (Glens Falls, N.Y.), The · RTT News

The FDA has cleared AngioDynamics to market its BioFlo Port with Endexo system. The device, which is implanted below the skin, is used to minimize the risk of blood clots among patients in need of prolonged or frequent access to the cardiovascular system for chemotherapy and other treatments.

View Full Article in:

Post-Star (Glens Falls, N.Y.), The · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Director, Site Quality Management
CareFusion
Palm Springs, CA